Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the potential of Atara's tabelecleucel (tab-cel), an immunotherapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) ahead of its Jan 10th FDA PDUFA

Ticker(s): ATRA

Who's the expert?

Institution: Stanford

Clinical Professor of Pediatrics in the Division of Hematology/ Oncology, Stem Cell Transplantation and Regenerative Medicine at Stanford.
Manages 2 patients with EBV+ PTLD.
Research focuses on Primary Immune Deficiencies Consortium (PIDTC) as well as long term outcomes following HSCT, in specific the neurocognitive function post HSCT.

Interview Goal

This conversation will focus on Atara Biotherapeutics' tabelecleucel (tab-cel). We'll get an expert's perspective on the likelihood of approval for tab-cel as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.